Abstracts tagged "Cohort Study"

Abstract Number: 0816 • ACR Convergence 2020
Treat-to-target Strategy in Patients with Rheumatoid Arthritis in Daily Clinical Practice -still Underused, but Superior to Routine Care: A Propensity Score Matched Analysis from the ATTRA Registry
Jakub Závada¹ and Lucie Nekvindova², ¹Revmatologický ústav, Praha 2, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
Background/Purpose: Treat-to-target (T2T) is a widely accepted management strategy for RA. It recommends attaining a goal of at least low disease activity (LDA) within 6…
Abstract Number: 1260 • ACR Convergence 2020
Longitudinal Relationships Between Depression, Anxiety and Cognition in Lupus
Kathleen Bingham¹, Juan Pablo Diaz-Martinez², Mahta Kakvan², Robin Green³, Dorcas Beaton⁴, Lesley Ruttan³, Carmela Tartaglia⁵, Marvin Fritzler⁶, May Choi⁷, Jiandong Su², Denisse Bonilla⁸, Nicole Anderson², Joan Wither², Patricia Katz⁹ and Zahi Touma¹⁰, ¹Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ²University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada, ⁴Institute for Work & Health, Toronto, ON, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁶Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸University Health Network, Toronto, Canada, ⁹University of California, San Francisco, Novato, CA, ¹⁰University of Toronto, Toronto, ON, Canada
Background/Purpose: There is a consistent relationship between cognition and depression and anxiety (affective symptoms) in lupus. Together, affective and cognitive symptoms represent among lupus’ most…
Abstract Number: 1729 • ACR Convergence 2020
Associations Between Patient Reported Outcomes and Impairments of Work and Activity in Patients with Rheumatoid Arthritis Who Achieved Clinical Remission; Retrospective Analysis Using the IORRA Database
Ryoko Sakai¹, Eiichi Tanaka², Eisuke Inoue³, Minako Sato⁴, Masaru Tanaka⁴, Katsunori Ikari¹, Atsuo Taniguchi¹, Hisashi Yamanaka⁵ and Masayoshi Harigai⁶, ¹Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Showa University Research Administration Center, Showa University, Tokyo, Japan, ⁴Eli Lilly Japan K.K., Tokyo, Japan, ⁵Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, ⁶Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan
Background/Purpose: Disease burden and subjective symptoms of rheumatoid arthritis (RA) remain even after achieving clinical remission or low disease activity. Impairments to work and societal/daily…
Abstract Number: 0389 • ACR Convergence 2020
Organ Specific Treatment Patterns of a Real-World, Electronic Health Record Cohort of Patients with Systemic Sclerosis
Kyle Kidwell¹, Leslie J. Crofford¹ and April Barnado¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Assembling large cohorts of patients with rare diseases is difficult and limits the power to assess outcomes in systemic sclerosis (SSc) studies. Treatment in…
Abstract Number: 0847 • ACR Convergence 2020
Impact of Hydroxychloroquine Treatment on Immunologic Markers in SLE Depends on Ethnicity
Laurence Magder¹, Daniel Goldman² and Michelle Petri², ¹University of Maryland, Baltimore, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: SLE patients with certain immunological markers (i.e., anti-DNA, low complement) are at higher risk of lupus nephritis and those with antiphospholipid antibodies are at…
Abstract Number: 1267 • ACR Convergence 2020
Perceived Stress During the COVID-19 Pandemic Independently Associates with Worse Patient-Reported Outcomes in Systemic Lupus Erythematosus (SLE)
Sarah Patterson¹, Laura Trupin², Kimberly DeQuattro¹, Cristina Lanata¹, Maria Dall'Era³, Jinoos Yazdany² and Patricia Katz², ¹UCSF, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³Division of Rheumatology, University of California, San Francisco, CA
Background/Purpose: Causes and risk factors for variations in SLE disease activity and symptom severity are incompletely understood. Prior studies suggest a link between stressful life…
Abstract Number: 1737 • ACR Convergence 2020
What Influences Fatigue Improvement in Rheumatoid Arthritis? A Prospective Cohort Study
Samar Aboulenain¹, Elie Donath¹ and Ozlem Pala², ¹University of Miami Miller School, West Palm Beach, FL, ²University of Miami Miller School, Fort Lauderdale, FL
Background/Purpose: Fatigue is a common and debilitating complication in patients with rheumatoid arthritis (RA). Its mechanism is not fully elucidated, and when persistent is often…
Abstract Number: 0391 • ACR Convergence 2020
Defining the Optimal Disease Duration of Early Diffuse Systemic Sclerosis for Clinical Trial Design
Robyn Domsic¹, Shiyao Gao², Maureen Laffoon², Steven Wisniewski³, Yuqing Zhang⁴, Robert Lafyatis⁵, Virginia Steen⁶ and Thomas Medsger⁷, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, ⁵University of Pittsburgh, Arlington, MA, ⁶Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁷University of Pittsburgh School of Medicine, Verona, PA
Background/Purpose: Clinical trials in early diffuse cutaneous systemic sclerosis (SSc) have historically used the modified Rodnan skin score (mRSS) as the primary outcome measure. These…
Abstract Number: 0869 • ACR Convergence 2020
Retinal Toxicity in a Multinational Inception Cohort of Systemic Lupus Patients on Hydroxychloroquine
Celline Almeida-Brasil¹, John Hanly², Murray Urowitz³, Ann Clarke⁴, Rosalind Ramsey-Goldman⁵, Caroline Gordon⁶, Michelle Petri⁷, Ellen M Ginzler⁸, Daniel J Wallace⁹, Sang-Cheol Bae¹⁰, Juanita Romero-Díaz¹¹, Mary Ann Dooley¹², Christine A. Peschken¹³, David Isenberg¹⁴, Anisur Rahman¹⁴, Susan Manzi¹⁵, Søren Jacobsen¹⁶, S. Sam Lim¹⁷, Ronald Van Vollenhoven¹⁸, Ola Nived¹⁹, Andreas Jönsen¹⁹, Diane Kamen²⁰, Cynthia Aranow²¹, Guillermo Ruiz-Irastorza²², Jorge Sanchez-Guerrero²³, Dafna Gladman²⁴, Paul Fortin²⁵, Graciela Alarcón²⁶, Joan Merrill²⁷, Kenneth Kalunian²⁸, Manuel Ramos-Casals²⁹, Kristjan Steinsson³⁰, Asad Zoma³¹, Anca Askanase³², Munther Khamashta³³, Ian Bruce³⁴, Murat Inanc³⁵ and Sasha Bernatsky³⁶, ¹McGill University, Montreal, Canada, ²QEII Health Sciences Centre, Halifax, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Calgary, Calgary, Canada, ⁵Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶University of Birmingham, Birmingham, England, United Kingdom, ⁷Johns Hopkins University School of Medicine, Baltimore, ⁸SUNY Downstate Health Sciences University, Brooklyn, ⁹Cedars-Sinai Medical Center, Beverly Hills, CA, ¹⁰Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹²UNC Health, Chapel Hil, ¹³University of Manitoba, Winnipeg, Canada, ¹⁴University College London, London, United Kingdom, ¹⁵Temple University, Philadelphia, ¹⁶University of Copenhagen, Copenhagen, Denmark, ¹⁷Emory University, Atlanta, GA, ¹⁸University of Amsterdam, Amsterdam, Netherlands, ¹⁹Lund University, Lund, Sweden, ²⁰Medical University of South Carolina, Charleston, SC, ²¹Feinstein Institutes for Medical Research, Manhasset, NY, ²²Hospital Universitario Cruces, Barakaldo, Spain, ²³University of Toronto, Toronto, Canada, ²⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²⁵CHU de Quebec - Universite Laval, Quebec, Canada, ²⁶Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama, ²⁷New York University, New York, ²⁸University of California San Diego, La Jolla, CA, ²⁹University of Barcelona, Barcelona, Spain, ³⁰Reykjavik University, Reykjavik, Iceland, ³¹University of Glasgow, Glasgow, United Kingdom, ³²Columbia University College of Physicians & Surgeons, New York, NY, ³³King's College London, London, United Kingdom, ³⁴The University of Manchester, Manchester, United Kingdom, ³⁵Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³⁶The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Despite the beneficial effects of hydroxychloroquine (HCQ) in systemic lupus erythematosus (SLE), retinal toxicity is a concern. Factors associated with retinal toxicity have been…
Abstract Number: 1280 • ACR Convergence 2020
COVID-19 Infections May Increase the Risk of SLE Flares
Leila Khalili¹, Yevgeniya Gartshteyn², Nancyanne Schmidt³, Teja Kapoor⁴, Laura Geraldino-Pardilla⁵ and Anca Askanase³, ¹Columbia University Medical Center, New York, NY, ²Columbia University College of Physicians and Surgeons, Glen Rock, NJ, ³Columbia University College of Physicians and Surgeons, New York, NY, ⁴Columbia University College of Physicians and Surgeons, Leonia, NJ, ⁵Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York
Background/Purpose: COVID-19 has overwhelmed the healthcare systems in New York City. Initial data from the Columbia Lupus Cohort suggests that 4% of patients with systemic…
Abstract Number: 1738 • ACR Convergence 2020
Promote Treat-to-Target for RA via Empowering Patients: A Cohort Study from China by Smart System of Disease Management (SSDM)
Jing Yang¹, Rong Mu², Chun Li³, Bin Wu⁴, Hongzhi Wang⁵, Wenqiang Fan⁶, Jinmei Zou⁷, Yu Zhang¹, Fen Li⁸, Xiaofeng Rong⁹, Jianhong Wu¹⁰, Yong Wang¹¹, Shengguang Li¹², Yi Zhao¹³, Xiaoqiang Hou¹⁴, Hui Xiao¹⁵, Yuhua Jia¹⁶, Bing Wu¹⁶, Miaomiao Song¹⁶, Fei Xiao¹⁶ and Zhanguo Li¹⁷, ¹Department of Rheumatology, Mianyang Central Hospital, Mianyang, China (People's Republic), ²People's Hospital, Beijing University Medical School, Beijing, Beijing, China (People's Republic), ³People's Hospital, Beijing University Medical School, beijing, China (People's Republic), ⁴Chongqing Hospital of Traditional Chinese Medicine, chongqing, China (People's Republic), ⁵The First Hospital of Jiaxing, Jiaxing, China (People's Republic), ⁶Central Hospital of XinXiang, Xinxiang, China (People's Republic), ⁷Department of Rheumatology, Mianyang Central Hospital, Mianyang, Sichuan, China (People's Republic), ⁸The Second Xiangya Hospital of Central South University, hunan, China (People's Republic), ⁹The First Affiliated Hospital of Chongqing Medical University, chongqing, China (People's Republic), ¹⁰Department of Rheumatology, Dazhou Central Hospital, Dazhou, China (People's Republic), ¹¹The first Hospital Affiliated to AMU (Southernwest Hospital), chongqing, China (People's Republic), ¹²Peking University International Hospital, Beijing, China (People's Republic), ¹³Xuanwu Hospital, Capital Medical University, Beijing, China, Beijing, China (People's Republic), ¹⁴Yichang Central People's Hospital, Beijing, China (People's Republic), ¹⁵Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ¹⁶Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), ¹⁷Peking University People’s Hospital, Xicheng, Beijing, China (People's Republic)
Background/Purpose: Treat-to-Target (T2T) strategy are critical for the treatment of RA, but Chinese rheumatologists can hardly provide patients with a complete assessment in the clinic…
Abstract Number: 0416 • ACR Convergence 2020
IgG4-related Retroperitoneal Fibrosis. Retrospective Cohort
Ernestina Angarola¹, Federico Jauk², Verónica Peuchot³, Maria Orlova¹, Melina Valeo², Javier Pollan¹ and Hernán Garcia Rivello², ¹Department of Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Department of Pathology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ³Internal Medicine Research Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina
Background/Purpose: The spectrum of IgG4-related disease (IgG4-RD) includes many diseases that were thought to be confined to a single organ, as the retroperitoneal fibrosis. Many…
Abstract Number: 0937 • ACR Convergence 2020
Late Cardiovascular Outcomes in Children with Kawasaki Disease: A Population-based Cohort Study
Cal Robinson¹, Rahul Chanchlani¹, Anastasia Gayowsky², Sandeep Brar³, Elizabeth Darling⁴, Catherine Demers⁴, Tapas Mondal¹, Rulan Parekh⁵, Hsien Seow⁴ and Michelle Batthish¹, ¹McMaster Children's Hospital, Hamilton, ON, Canada, ²ICES McMaster, Hamilton, ON, Canada, ³University of California, San Fransisco, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Toronto, Toronto, Canada
Background/Purpose: Kawasaki disease (KD) is a common childhood vasculitis associated with coronary artery aneurysms (CAA). Based on our recent work, the incidence of KD has…
Abstract Number: 1304 • ACR Convergence 2020
Uveitis Occurrence in Early Inflammatory Back Pain: Five Years Data from a Prospective French Nationwide Cohort
Daniel Wendling¹, Clement Prati², Thierry Lequerre³, Corinne Miceli-Richard⁴, Maxime Dougados⁵, Anna Molto⁶ and Xavier Guillot⁷, ¹CHU Besançon, department of rheumatology, Besancon, France, ²Rheumatology, University Teaching Hospital, Besançon, France, ³Rheumatology, University Teaching Hospital, Rouen, France, ⁴Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ⁵Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France, ⁶Rheumatology Department, Cochin Hospital, APHP, Paris, France, Paris, France, ⁷CHU Reunion, Saint Denis, Reunion
Background/Purpose: Uveitis is the most frequent extra rheumatological manifestation in axial Spondyloarthritis (SpA). DESIR is a prospective multicenter cohort of patients with early inflammatory back…
Abstract Number: 1837 • ACR Convergence 2020
Clinical Outcomes in Lupus Nephritis by Renal Response Status: A Retrospective Analysis of the Hopkins Lupus Cohort
Michelle Petri¹, Qinggong Fu², Yulia Green³, Anuradha Madan⁴, Daniel Goldman⁵ and Selin Cooper-Blenkinsopp⁶, ¹Johns Hopkins University School of Medicine, Baltimore, ²GlaxoSmithKline, Upper Providence, ³GlaxoSmithKline, Uxbridge, ⁴GlaxoSmithKline, Collegeville, ⁵Johns Hopkins University School of Medicine, Timonium, MD, ⁶GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: A retrospective analysis of the Hopkins Lupus Cohort (a prospective, longitudinal study of patients [pts] with systemic lupus erythematosus) reported that renal response (complete/partial/none)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].